Timothy P. Noyes - Jan 3, 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Jan 3, 2023
Transactions value $
-$373,976
Form type
4
Date filed
1/5/2023, 04:00 PM
Previous filing
Dec 2, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $32.1K +15K $2.14* 15K Jan 3, 2023 Direct F1
transaction AVTE Common Stock Sale -$320K -11.9K -79.51% $26.80 3.07K Jan 3, 2023 Direct F1, F2
transaction AVTE Common Stock Sale -$63.3K -2.27K -73.77% $27.90 806 Jan 3, 2023 Direct F1, F3
transaction AVTE Common Stock Sale -$22.8K -791 -98.14% $28.78 15 Jan 3, 2023 Direct F1, F4
transaction AVTE Common Stock Sale -$447 -15 -100% $29.82 0 Jan 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -15K -3.14% $0.00 463K Jan 3, 2023 Common Stock 15K $2.14 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.26 to $27.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.32 to $28.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.56 to $29.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.